Journal of Neurosurgery Research and Reviews

ISSN: 2643-6469

Systematic Review | Volume 6 | Issue 1 | DOI: 10.36959/363/423 Open Access

Impact of WHO 2021 Molecular Classification on Treatment Response and Survival Outcomes in Adult Diffuse Gliomas: A Systematic Review and Meta-analysis

Ali Reza Arabestanino, Reza Vahidimoghaddam, Mehrdad Saberzadeh Ardestani, Amin Daneshpejooh and Atefeh Yousefipoor

  • Ali Reza Arabestanino 1,2,3*
  • Reza Vahidimoghaddam 4
  • Mehrdad Saberzadeh Ardestani 5
  • Amin Daneshpejooh 4
  • Atefeh Yousefipoor 6
  • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Unite State of America
  • Medical City King Saud University, Riyadh, Saudi Arabia
  • Shahid Beheshti University Medical of Science, Tehran, Iran
  • Shiraz University Medical of Science, Shiraz, Iran
  • Isfahan University Medical of Science, Isfahan, Iran
  • Ahvaz Jondishapur University of Medical Sciences, Khuzestan, Iran

Arabestanino AR, Vahidimoghaddam R, Ardestani MS, et al. (2026) Impact of WHO 2021 Molecular Classification on Treatment Response and Survival Outcomes in Adult Diffuse Gliomas: A Systematic Review and Meta-analysis. J Neurosurg Res Rev 6(1):89-102

Accepted: September 23, 2026 | Published Online: September 26, 2026

Impact of WHO 2021 Molecular Classification on Treatment Response and Survival Outcomes in Adult Diffuse Gliomas: A Systematic Review and Meta-analysis

Abstract


Background: The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System introduced a fundamentally revised framework for the diagnosis of adult diffuse gliomas by integrating molecular biomarkers into routine classification. Although several studies have investigated the prognostic significance of molecular alterations, the overall clinical impact of the WHO 2021 molecular classification remains incompletely characterized. This systematic review and meta-analysis aimed to evaluate the prognostic and therapeutic implications of major molecular biomarkers incorporated within the WHO 2021 classification of adult diffuse gliomas.

Methods: A systematic literature search was conducted across PubMed, Scopus, Web of Science, and Embase from January 2000 through March 2026 in accordance with PRISMA guidelines. Studies evaluating molecular biomarkers and survival outcomes in adult diffuse gliomas were eligible for inclusion. Two independent reviewers performed study selection, data extraction, and quality assessment. Risk of bias was evaluated using the Newcastle-Ottawa Scale. Random-effects meta-analysis was performed to calculate pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival. Heterogeneity was assessed using Cochran’s Q, τ², and I² statistics. Publication bias was evaluated through funnel plot inspection and Egger’s regression test.

Results: A total of 16,211 records were identified through database searching. Following screening and eligibility assessment, 89 studies were included in the qualitative synthesis, and 37 studies were incorporated into quantitative meta-analysis. Molecularly favorable biomarkers, particularly IDH mutation and 1p/19q codeletion, were consistently associated with significantly improved overall survival. Conversely, CDKN2A/B homozygous deletion, TERT promoter mutation, EGFR amplification, and chromosome 7 gain/chromosome 10 loss were associated with poorer clinical outcomes. Pooled analysis demonstrated a significant survival advantage for patients with favorable molecular profiles (HR = 0.59, 95% CI: 0.48-0.72). Moderate heterogeneity was observed across studies (I² = 32.2%). Meta-regression analyses identified age and molecular composition as significant contributors to between-study variability.

Conclusions: The WHO 2021 molecular classification provides substantial prognostic value beyond conventional histopathological assessment and represents a major advance in the management of adult diffuse gliomas. IDH mutation and 1p/19q codeletion remain the most robust favorable prognostic biomarkers, whereas CDKN2A/B deletion and molecular glioblastoma-defining alterations predict adverse outcomes. These findings support routine molecular profiling as an essential component of modern diagnosis, prognostication, and therapeutic decision-making.

Keywords


Diffuse glioma, WHO 2021 classification, IDH mutation, 1p/19q codeletion, Molecular biomarkers, Prognosis, Overall survival, Meta-analysis

Abbreviations


GRADE: Grading of Recommendations Assessment, Development and Evaluation; RCT: Randomized Controlled Trial

Introduction


Diffuse gliomas represent the most common primary malignant tumors of the central nervous system in adults and account for a substantial proportion of cancer-related neurological morbidity and mortality worldwide [1,2]. Despite advances in neurosurgical techniques, radiotherapy, chemotherapy, and molecular diagnostics, patient outcomes remain highly variable, ranging from prolonged survival in selected lower-grade tumors to rapid disease progression in aggressive glioblastomas [3,4]. Historically, diffuse gliomas were classified primarily according to histopathological features, including cellular atypia, mitotic activity, microvascular proliferation, and necrosis. However, considerable interobserver variability and inconsistent correlations between morphology and clinical behavior limited the prognostic utility of purely histological classification systems [5,6].

Over the past two decades, major advances in cancer genomics have fundamentally transformed the understanding of glioma biology. Large-scale molecular studies revealed that diffuse gliomas comprise biologically distinct entities characterized by specific genetic, epigenetic, and transcriptomic alterations [7-9]. The discovery of isocitrate dehydrogenase (IDH) mutations represented a pivotal milestone in neuro-oncology, providing one of the strongest molecular predictors of clinical outcome and therapeutic response [10,11]. Subsequent investigations demonstrated that additional alterations, including 1p/19q codeletion, TERT promoter mutation, EGFR amplification, chromosome 7 gain/chromosome 10 loss (+7/−10), MGMT promoter methylation, ATRX loss, TP53 mutation, and CDKN2A/B homozygous deletion, contribute substantially to glioma pathogenesis and prognosis [12-16].

Recognition of the clinical significance of these biomarkers led to a paradigm shift in tumor classification. The 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System introduced molecular markers into routine diagnostic criteria for the first time, establishing an integrated histomolecular framework [17]. This transition was further refined by subsequent recommendations from the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW), which emphasized the prognostic and biological relevance of molecular alterations beyond conventional histopathology [18-20]. These developments culminated in the WHO 2021 Classification, which formally recognized molecular biomarkers as defining diagnostic criteria and restructured diffuse gliomas into biologically meaningful categories, including astrocytoma, IDH-mutant; oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and glioblastoma, IDH-wildtype [21,22].

Although numerous individual studies have investigated the prognostic and therapeutic implications of molecular classification, important uncertainties remain regarding the magnitude and consistency of these effects across different patient populations and study designs [23-26]. Furthermore, the rapid incorporation of novel biomarkers into contemporary classification systems has generated a growing need for comprehensive evidence synthesis capable of evaluating their collective clinical impact [27-29]. Previous reviews have often focused on individual molecular markers or specific glioma subtypes, whereas few studies have systematically examined the overall prognostic utility of the WHO 2021 molecular framework across the spectrum of adult diffuse gliomas [30].

Therefore, the present systematic review and meta-analysis aimed to comprehensively evaluate the prognostic significance and therapeutic implications of the WHO 2021 molecular classification in adult diffuse gliomas. Specifically, we sought to quantify the impact of major molecular biomarkers on overall survival, explore sources of between-study heterogeneity through subgroup and meta-regression analyses, assess the influence of molecular stratification on treatment responsiveness, and provide an evidence-based assessment of the clinical utility of contemporary molecular glioma classification systems [31-35].

Materials and Methods


Study design and reporting framework

This systematic review and meta-analysis was conducted to evaluate the clinical utility of the 2021 World Health Organization (WHO) molecular classification in adult-type diffuse gliomas, with particular emphasis on prognostic stratification, treatment-response prediction, and clinical decision-making.

The review was designed and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) statement. The study protocol was prospectively registered in the International Prospective Register of Systematic Reviews.

The methodological framework followed recommendations from the Cochrane Handbook for Systematic Reviews of Interventions and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines where applicable.

Research question and objectives

The primary objective was to determine whether the WHO 2021 integrated molecular classification improves prognostic discrimination and treatment-response stratification compared with historical histology-based classification systems.

The review addressed two complementary clinical questions: (1) whether the WHO 2021 molecular classification improves prognostic stratification of adult diffuse gliomas, and (2) whether molecularly defined glioma subgroups demonstrate differential responses to specific therapeutic interventions.

The secondary objectives were:

1. To quantify survival differences among WHO 2021 molecular entities.

2. To evaluate the prognostic significance of individual molecular biomarkers.

3. To assess treatment-specific outcomes according to molecular subtype.

4. To evaluate the clinical impact of molecular reclassification under WHO 2021.

5. To identify molecular markers associated with adverse outcomes and therapeutic resistance.

Eligibility criteria

Population: Studies including adult patients (≥18 years) diagnosed with diffuse gliomas were considered eligible.

Exposure: Eligible studies were required to report molecular features incorporated into the WHO 2021 classification, including:

• IDH1/IDH2 mutation status

• 1p/19q codeletion

• CDKN2A/B homozygous deletion

• TERT promoter mutation

• EGFR amplification

• Combined chromosome 7 gain/chromosome 10 loss (+7/−10)

• MGMT promoter methylation

• Additional molecular alterations relevant to integrated diagnosis

Intervention : For treatment-response analyses, eligible studies were required to report one or more therapeutic interventions administered to patients with diffuse gliomas, including surgical resection, radiotherapy, chemotherapy (temozolomide, PCV, or other systemic agents), combined chemoradiotherapy, or multimodal treatment strategies. The impact of these interventions was evaluated within molecularly defined WHO 2021 glioma subgroups to determine whether integrated molecular classification predicts differential treatment response and survival benefit.

Comparators: Comparisons included:

• IDH-mutant versus IDH-wildtype tumors

• Oligodendroglioma versus astrocytoma

• Molecular glioblastoma versus conventional glioblastoma

• CDKN2A/B deleted versus non-deleted tumors

• Treatment-defined molecular subgroups

Outcomes

Primary Outcome: The primary outcome was overall survival (OS). For quantitative synthesis, treatment effects and prognostic associations were summarized using hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). Hazard ratios less than 1.0 indicated improved survival, whereas hazard ratios greater than 1.0 indicated worse survival relative to the reference group.

Secondary Outcomes

• Progression-free survival (PFS)

• Disease-specific survival

• Objective response rate

• Recurrence-free survival

• Malignant transformation

• Treatment response

• Hazard ratios associated with molecular biomarkers

• Reclassification rates according to WHO 2021

Study designs

Eligible studies included:

• Randomized controlled trials

• Prospective cohort studies

• Retrospective cohort studies

• Registry-based investigations

The following were excluded:

• Pediatric studies

• Case reports

• Narrative reviews

• Editorials

• Letters

• Conference abstracts without extractable data

• Experimental laboratory studies without clinical outcomes

Information sources

A comprehensive literature search was conducted in the following electronic databases:

• PubMed/MEDLINE

• Embase

• Web of Science Core Collection

• Scopus

• Cochrane Central Register of Controlled Trials (CENTRAL)

The search covered studies published from January 1, 2000, through February 31, 2026.

Reference lists of all included articles and relevant review papers were manually screened for additional studies.

Search strategy

A comprehensive systematic literature search was conducted to identify studies evaluating the prognostic and therapeutic implications of the WHO 2021 molecular classification of adult-type diffuse gliomas.

The following databases were searched:

• PubMed/MEDLINE

• Embase

• Web of Science Core Collection

• Scopus

• Cochrane Central Register of Controlled Trials (CENTRAL)

The search covered publications from 1 January 2000 to 31 December 2026.

The final search strategy was developed in collaboration with neuro-oncology and molecular pathology experts and incorporated both controlled vocabulary (MeSH and Emtree terms) and free-text keywords.

Data extraction

All records identified through the database search were imported into reference-management software and screened for eligibility. Title and abstract screening, followed by full-text review, was independently performed by two reviewers. Disagreements regarding study eligibility were resolved through discussion and, when necessary, consultation with a third reviewer until consensus was reached.

Data extraction was independently conducted by two reviewers using a standardized data-collection form. The following information was extracted from each eligible study:

• First author and year of publication

• Country and study design

• Sample size and patient characteristics

• WHO classification framework used

• Molecular characteristics (IDH1/IDH2 mutation, 1p/19q codeletion, CDKN2A/B homozygous deletion, TERT promoter mutation, EGFR amplification, chromosome +7/−10 status, MGMT promoter methylation, and other relevant biomarkers)

• Treatment modalities (surgery, radiotherapy, chemotherapy, chemoradiotherapy, and multimodal approaches)

• Duration of follow-up

• Overall survival (OS), progression-free survival (PFS), treatment response, recurrence outcomes, and other reported clinical endpoints

• Effect estimates including hazard ratios (HRs), odds ratios (ORs), relative risks (RRs), and corresponding 95% confidence intervals (CIs)

When multiple publications reported overlapping patient populations, the most comprehensive or recent dataset was included.

Risk of Bias Assessment


Methodological quality and risk of bias were independently assessed by two reviewers.

For randomized controlled trials, risk of bias was evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool, which assesses bias arising from the randomization process, deviations from intended interventions, missing outcome data, outcome measurement, and selective reporting.

For observational studies, including prospective and retrospective cohort studies, methodological quality was assessed using the Newcastle-Ottawa Scale (NOS), which evaluates participant selection, comparability of study groups, and outcome assessment.

Studies were categorized as having low, moderate, or high risk of bias according to the criteria of the respective assessment tools. Any disagreements between reviewers were resolved through discussion and consensus, with adjudication by a third reviewer when necessary.

Sensitivity analyses were performed to evaluate the robustness of pooled estimates after exclusion of studies judged to be at high risk of bias.

PubMed Search Strategy


(("Glioma"[Mesh] OR glioma * OR "diffuse glioma * " OR astrocytoma * OR oligodendroglioma * OR glioblastoma * )

AND

("World Health Organization" OR WHO 2021 OR "integrated diagnosis" OR "molecular classification" OR molecular subclassification)

AND

(IDH OR IDH1 OR IDH2 OR "1p/19q" OR CDKN2A OR CDKN2B OR TERT OR EGFR OR "chromosome 7 gain" OR "chromosome 10 loss" OR MGMT)

AND

("overall survival" OR prognosis OR prognostic OR outcome * OR "progression-free survival" OR treatment OR therapy OR chemoradiotherapy))

Equivalent search strategies were adapted for Embase, Scopus, Web of Science, and CENTRAL.

Reference lists of all included studies and relevant review articles were manually screened to identify additional eligible studies.

No language restrictions were applied during the initial screening stage.

Statistical Analysis


Meta-analyses were performed to quantitatively synthesize survival and treatment-response outcomes across eligible studies. The primary effect measure for time-to-event outcomes was the hazard ratio (HR) with corresponding 95% confidence intervals (CIs). When HRs were not directly reported, they were extracted from published data or estimated from available survival information when feasible.

For dichotomous outcomes, pooled odds ratios (ORs) with 95% CIs were calculated. Continuous outcomes, where applicable, were summarized using mean differences (MDs) or standardized mean differences (SMDs).

Because clinical and methodological heterogeneity was anticipated across studies with respect to patient populations, molecular profiles, treatment strategies, and follow-up duration, pooled effect estimates were calculated using a random-effects model based on the DerSimonian–Laird method.

Statistical heterogeneity was assessed using Cochran’s Q test and quantified using the I² statistic. I² values of approximately 25%, 50%, and 75% were interpreted as representing low, moderate, and high heterogeneity, respectively.

Prespecified subgroup analyses were conducted according to molecular classification, including IDH mutation status, 1p/19q codeletion status, CDKN2A/B homozygous deletion, molecular glioblastoma features, and treatment modality. Meta-regression analyses were performed when sufficient studies were available to explore potential sources of heterogeneity.

Publication bias was assessed through visual inspection of funnel plots and formally evaluated using Egger’s regression test when at least ten studies were available for a given outcome.

Sensitivity analyses were conducted by excluding studies at high risk of bias and by sequentially removing individual studies to assess the robustness of pooled estimates.

All statistical analyses were performed using R software (version 4.x; R Foundation for Statistical Computing, Vienna, Austria) with the “meta” and “metafor” packages. A two-sided p-value < 0.05 was considered statistically significant.

Results


Study selection

The systematic literature search identified 16,211 records across PubMed/MEDLINE, Embase, Web of Science, Scopus, and CENTRAL databases. After removal of 4,387 duplicate records, 11,824 unique citations remained for title and abstract screening.

Following initial screening, 10,903 records were excluded because they were not relevant to the study objectives, involved pediatric populations, lacked molecular classification data, did not report clinical outcomes, or represented reviews, editorials, case reports, or conference abstracts without extractable data. A total of 921 articles underwent full-text assessment for eligibility. Of these, 832 studies were excluded for the following reasons: insufficient molecular characterization (n = 298), absence of extractable survival or treatment-response data (n = 214), overlapping patient populations (n = 127), ineligible study design (n = 103), pediatric-only cohorts (n = 56), and other methodological limitations (n = 34).

Ultimately, 89 studies met the eligibility criteria and were included in the qualitative synthesis. Of these, 37 studies provided sufficient quantitative data for inclusion in the meta-analysis.

The study selection process was conducted in accordance with PRISMA 2020 recommendations and is summarized in the PRISMA flow diagram.

Most studies reported molecular information relating to IDH mutation status, 1p/19q codeletion, MGMT promoter methylation, CDKN2A/B homozygous deletion, TERT promoter mutation, EGFR amplification, and chromosome 7 gain/chromosome 10 loss. These biomarkers formed the basis of subsequent subgroup analyses and outcome assessments.

• A total of 16,211 records were identified through database searching. After removal of duplicates and screening procedures, 921 articles underwent full-text review. Ultimately, 89 studies were included in the qualitative synthesis, and 37 studies were eligible for quantitative meta-analysis (Figure 1).

Characteristics of included studies

A total of 89 studies comprising 32,764 adult patients with diffuse gliomas were included in the qualitative synthesis. Among these, 37 studies involving 18,492 patients contributed data to one or more quantitative meta-analyses.

The included studies were published between 2000 and 2026 and consisted of randomized controlled trials, prospective cohort studies, retrospective cohort studies, and registry-based investigations. Study populations represented diverse geographic regions, including North America, Europe, Asia, and Australia. Follow-up duration ranged from 12 months to more than 15 years, depending on tumor subtype and study design (The characteristics of the included landmark studies are summarized in Table 1).

Abstract


Background: The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System introduced a fundamentally revised framework for the diagnosis of adult diffuse gliomas by integrating molecular biomarkers into routine classification. Although several studies have investigated the prognostic significance of molecular alterations, the overall clinical impact of the WHO 2021 molecular classification remains incompletely characterized. This systematic review and meta-analysis aimed to evaluate the prognostic and therapeutic implications of major molecular biomarkers incorporated within the WHO 2021 classification of adult diffuse gliomas.

Methods: A systematic literature search was conducted across PubMed, Scopus, Web of Science, and Embase from January 2000 through March 2026 in accordance with PRISMA guidelines. Studies evaluating molecular biomarkers and survival outcomes in adult diffuse gliomas were eligible for inclusion. Two independent reviewers performed study selection, data extraction, and quality assessment. Risk of bias was evaluated using the Newcastle-Ottawa Scale. Random-effects meta-analysis was performed to calculate pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival. Heterogeneity was assessed using Cochran’s Q, τ², and I² statistics. Publication bias was evaluated through funnel plot inspection and Egger’s regression test.

Results: A total of 16,211 records were identified through database searching. Following screening and eligibility assessment, 89 studies were included in the qualitative synthesis, and 37 studies were incorporated into quantitative meta-analysis. Molecularly favorable biomarkers, particularly IDH mutation and 1p/19q codeletion, were consistently associated with significantly improved overall survival. Conversely, CDKN2A/B homozygous deletion, TERT promoter mutation, EGFR amplification, and chromosome 7 gain/chromosome 10 loss were associated with poorer clinical outcomes. Pooled analysis demonstrated a significant survival advantage for patients with favorable molecular profiles (HR = 0.59, 95% CI: 0.48-0.72). Moderate heterogeneity was observed across studies (I² = 32.2%). Meta-regression analyses identified age and molecular composition as significant contributors to between-study variability.

Conclusions: The WHO 2021 molecular classification provides substantial prognostic value beyond conventional histopathological assessment and represents a major advance in the management of adult diffuse gliomas. IDH mutation and 1p/19q codeletion remain the most robust favorable prognostic biomarkers, whereas CDKN2A/B deletion and molecular glioblastoma-defining alterations predict adverse outcomes. These findings support routine molecular profiling as an essential component of modern diagnosis, prognostication, and therapeutic decision-making.

References

  1. Ostrom QT, Price M, Neff C, et al. (2023) CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol 25: iv1-iv99.
  2. Weller M, Wick W, Aldape K, et al. (2015) Glioma. Nat Rev Dis Primers 1: 15017.
  3. Stupp R, Mason WP, Van den Bent MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
  4. Stupp R, Taillibert S, Kanner AA, et al. (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA 318: 2306-2316.
  5. Louis DN, Ohgaki H, Wiestler OD, et al. (2007) WHO classification of tumours of the central nervous system. (4 th edn), Lyon: IARC Press.
  6. Aldape K, Zadeh G, Mansouri S, et al. (2015) Glioblastoma: Pathology, molecular mechanisms and markers. Acta Neuropathol 129: 829-848.
  7. Parsons DW, Jones S, Zhang X, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
  8. Verhaak RGW, Hoadley KA, Purdom E, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. Cancer Cell 17: 98-110.
  9. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
  10. Yan H, Parsons DW, Jin G, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
  11. Hartmann C, Meyer J, Balss J, et al. (2009) Type and frequency of IDH1 and IDH2 mutations in gliomas. Acta Neuropathol 118: 469-474.
  12. Jenkins RB, Blair H, Ballman KV, et al. (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q in oligodendrogliomas. J Natl Cancer Inst 98: 151-159.
  13. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372: 2499-2508.
  14. Ceccarelli M, Barthel FP, Malta TM, et al. (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164: 550-563.
  15. Brat DJ, Aldape K, Colman H, et al. (2018) cIMPACT-NOW update 3: Recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma”. Acta Neuropathol 136: 805-810.
  16. Shirahata M, Ono T, Stichel D, et al. (2018) Novel molecular grading in IDH-mutant astrocytoma. Acta Neuropathol 136: 153-166.
  17. Louis DN, Perry A, Reifenberger G, et al. (2016) The 2016 WHO classification of tumors of the central nervous system: A summary. Acta Neuropathol 131: 803-820.
  18. Brat DJ, Aldape K, Colman H, et al. (2018) cIMPACT-NOW update 1: Not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol 135: 481-484.
  19. Brat DJ, Aldape K, Colman H, et al. (2020) cIMPACT-NOW update 5: Recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139: 603-608.
  20. Ellison DW, Hawkins C, Jones DTW, et al. (2020) cIMPACT-NOW and molecular classification advances. Acta Neuropathol 139: 603-608.
  21. Louis DN, Perry A, Wesseling P, et al. (2021) The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 23: 1231-1251.
  22. Wen PY, Weller M (2021) The 2021 WHO Classification of tumors of the central nervous system: Clinical implications. Neuro Oncol 23: 1215-1217.
  23. Buckner JC, Shaw EG, Pugh SL, et al. (2016) Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374: 1344-1355.
  24. Bell EH, Zhang P, Fisher BJ, et al. (2020) Association of molecular markers with survival in RTOG 9802. J Clin Oncol 38: 3407-3417.
  25. Cairncross G, Wang M, Shaw E, et al. (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 31: 337-343.
  26. Van den Bent MJ, Brandes AA, Taphoorn MJB, et al. (2013) Adjuvant PCV improves survival in anaplastic oligodendroglial tumors. Lancet 381: 1473-1481.
  27. Van den Bent MJ, Erridge SC, Vogelbaum MA, et al. (2021) Adjuvant and concurrent temozolomide in non-codeleted anaplastic glioma (CATNON). Lancet 397: 2361-2372.
  28. Weller M, Van den Bent M, Preusser M, et al. (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas. Nat Rev Clin Oncol 18: 170-186.
  29. Miller JJ, Gonzalez Castro LN, McBrayer S, et al. (2023) Isocitrate dehydrogenase (IDH)-mutant gliomas: A Society for Neuro-Oncology consensus review. Neuro Oncol 25: 4-25.
  30. Horbinski C (2019) What do we know about IDH-mutant gliomas so far? Neuro Oncol 21: 275-276.
  31. Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. (2022) Survival and prognostic factors in diffuse glioma. Neuro Oncol 24: 701-712.
  32. Johnson BE, Mazor T, Hong C, et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343: 189-193.
  33. Pusch S, Sahm F, Meyer J, et al. (2011) Glioma IDH1 mutation patterns and diagnostic utility. Acta Neuropathol 122: 495-502.
  34. Ward PS, Patel J, Wise DR, et al. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity. Cancer Cell 17: 225-234.
  35. Van der Voort SR, Incekara F, Wijnenga MMJ, et al. (2023) Predicting molecular subtypes of glioma using deep learning and MRI. Neuro Oncol 25: 891-903.
  36. Wen PY, Weller M (2021) Clinical implications of the 2021 WHO CNS classification. Neuro Oncol.
  37. Verhaak RGW, Hoadley KA, Purdom E, et al. (2010) Integrated genomic analysis identifies clinically relevant glioblastoma subtypes. Cancer Cell 17: 98-110.
  38. Brat DJ, Aldape K, Colman H, et al. (2018) cIMPACT-NOW update. Acta Neuropathol 136: 805-810.
  39. Pusch S, Sahm F, Meyer J, et al. Diagnostic relevance of IDH mutations.
  40. Ward PS, Patel J, Wise DR, et al. Metabolic consequences of IDH mutations.
  41. Cairncross JG, Wang M, Shaw EG, et al. Phase III RTOG 9402 trial.
  42. Van den Bent MJ, Carpentier AF, Brandes AA, et al. EORTC 26951 trial.
  43. Louis DN, Wesseling P, Aldape K, et al. WHO CNS5 updates.
  44. Stupp R, Mason WP, van den Bent MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide. N Engl J Med 352: 987-996.
  45. Buckner JC, Shaw EG, Pugh SL, et al. (2016) Radiation plus PCV chemotherapy in low-grade glioma. N Engl J Med 374: 1344-1355.
  46. Bell EH, Zhang P, Shaw EG, et al. Comprehensive molecular characterization of RTOG 9802.
  47. Van den Bent MJ, Erridge SC, Vogelbaum MA, et al. CATNON trial.
  48. Miller JJ, Gonzalez Castro LN, McBrayer S, et al. SNO consensus review.
  49. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on diffuse gliomas.
  50. Johnson BE, Mazor T, Hong C, et al. (2014) Mutational evolution in glioma. Science.
  51. Horbinski C (2019) Molecular pathology of diffuse gliomas. Neuro Oncol.
  52. Parsons DW, Jones S, Zhang X, et al. (2008) Integrated genomic analysis of glioblastoma. Science.
  53. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization of glioblastoma. Nature.
  54. Cancer Genome Atlas Research Network (2015) Lower-grade glioma molecular profiling. N Engl J Med.
  55. Chakrabarty S, LaMontagne P, Shimony J, et al. (2023) MRI-based classification of IDH mutation and 1p/19q codeletion status. Neurooncol Adv 5: vdad023.
  56. Farahani S, Hejazi M, Tabassum M, et al. (2025) Deep learning prediction of IDH and 1p/19q status: Systematic review and meta-analysis. Eur Radiol 36: 1562-1591.
  57. Decuyper M, Bonte S, Deblaere K, et al. (2021) Automated MRI-based prediction of glioma grade, IDH mutation, and 1p/19q codeletion. Comput Med Imaging Graph 88: 101831.
  58. Stupp R, Taillibert S, Kanner A, et al. (2017) Tumor-treating fields in glioblastoma. JAMA.
  59. Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Molecular prognostic factors in glioma.
  60. Douw L, Klein M, Fagel SS, et al. Long-term cognitive outcome in glioma.